FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What’s Next?

Pharmacy Times·Mar 26

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The FDA has issued warning letters to telehealth companies regarding the marketing of compounded GLP-1s, with reports indicating that 30 such letters were sent. The warnings appear to be related to allegedly misleading marketing practices. The action is seen as part of a broader effort by the FDA to crack down on the compounding of GLP-1s.

Full coverage

FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down – What’s Next?

Spencer Fane·Feb 24

FDA warns telehealth companies over compounded GLP-1s

Endpoints News·Jun 17

FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing

Pharmaceutical Commerce·Mar 4

FDA ramps up its pushback against compounded GLP-1s

pharmaphorum·Mar 4

FDA issues 30 warning letters to online GLP-1 compounders

Medical Marketing and Media·Mar 4

Why the FDA Issued 30 Warning Letters to Telehealth Sites Marketing Compounded GLP-1s

PharmTech.com·Mar 4

Feds warn telehealth companies about "illegal marketing" of compounded GLP-1s

WRTV·Apr 20

FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s

BioSpace·Mar 4

View original report at Pharmacy Times ↗

Fetching the latest headlines…